Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Lassa Fever | 31 | 2024 | 97 | 8.130 |
Why?
|
Antimalarials | 61 | 2023 | 913 | 7.130 |
Why?
|
Malaria, Falciparum | 56 | 2023 | 1075 | 6.750 |
Why?
|
Artemisinins | 38 | 2022 | 217 | 6.560 |
Why?
|
Nigeria | 81 | 2024 | 782 | 5.920 |
Why?
|
Lassa virus | 27 | 2024 | 100 | 5.830 |
Why?
|
Amodiaquine | 32 | 2023 | 58 | 5.280 |
Why?
|
Plasmodium falciparum | 42 | 2022 | 1738 | 4.420 |
Why?
|
Drug Resistance | 21 | 2022 | 1591 | 2.310 |
Why?
|
Fluorenes | 18 | 2023 | 160 | 2.260 |
Why?
|
Ethanolamines | 18 | 2023 | 152 | 2.100 |
Why?
|
Ebolavirus | 13 | 2020 | 250 | 1.990 |
Why?
|
Protozoan Proteins | 12 | 2022 | 843 | 1.970 |
Why?
|
Genome, Viral | 11 | 2024 | 670 | 1.870 |
Why?
|
Parasitemia | 19 | 2019 | 164 | 1.770 |
Why?
|
Chiroptera | 2 | 2024 | 62 | 1.700 |
Why?
|
Hemorrhagic Fever, Ebola | 14 | 2020 | 424 | 1.680 |
Why?
|
Disease Outbreaks | 16 | 2022 | 1759 | 1.290 |
Why?
|
Monkeypox virus | 3 | 2023 | 43 | 1.000 |
Why?
|
Anemia | 14 | 2019 | 1511 | 1.000 |
Why?
|
Dihydropteroate Synthase | 2 | 2021 | 27 | 0.980 |
Why?
|
Chloroquine | 9 | 2015 | 276 | 0.970 |
Why?
|
Drug Combinations | 30 | 2023 | 2077 | 0.960 |
Why?
|
RNA, Viral | 9 | 2023 | 2864 | 0.950 |
Why?
|
Tetrahydrofolate Dehydrogenase | 2 | 2021 | 133 | 0.940 |
Why?
|
Multidrug Resistance-Associated Proteins | 4 | 2020 | 105 | 0.930 |
Why?
|
Genomics | 14 | 2024 | 5929 | 0.890 |
Why?
|
Antigens, Viral | 9 | 2020 | 995 | 0.890 |
Why?
|
Malaria | 10 | 2024 | 1246 | 0.880 |
Why?
|
Phylogeny | 12 | 2024 | 2832 | 0.870 |
Why?
|
Nucleoproteins | 3 | 2020 | 110 | 0.840 |
Why?
|
RNA Viruses | 2 | 2022 | 109 | 0.830 |
Why?
|
Insect Viruses | 1 | 2022 | 15 | 0.810 |
Why?
|
Arboviruses | 1 | 2022 | 12 | 0.800 |
Why?
|
Polymorphism, Genetic | 8 | 2021 | 4247 | 0.770 |
Why?
|
Dengue Virus | 1 | 2024 | 202 | 0.770 |
Why?
|
Hemorrhagic Disease Virus, Rabbit | 1 | 2021 | 2 | 0.760 |
Why?
|
Abattoirs | 1 | 2021 | 7 | 0.760 |
Why?
|
Caliciviridae Infections | 1 | 2021 | 28 | 0.750 |
Why?
|
Shiga-Toxigenic Escherichia coli | 1 | 2021 | 24 | 0.740 |
Why?
|
Pyrimethamine | 7 | 2021 | 95 | 0.740 |
Why?
|
Food Microbiology | 1 | 2021 | 73 | 0.740 |
Why?
|
Aedes | 1 | 2022 | 100 | 0.730 |
Why?
|
Coronavirus | 1 | 2023 | 155 | 0.720 |
Why?
|
Extensively Drug-Resistant Tuberculosis | 1 | 2021 | 85 | 0.720 |
Why?
|
Antibodies, Viral | 11 | 2020 | 3211 | 0.710 |
Why?
|
Dengue | 1 | 2024 | 257 | 0.710 |
Why?
|
HIV Integrase | 1 | 2022 | 121 | 0.710 |
Why?
|
Membrane Transport Proteins | 6 | 2020 | 1028 | 0.700 |
Why?
|
Sulfadoxine | 5 | 2021 | 47 | 0.680 |
Why?
|
Food Contamination | 1 | 2021 | 194 | 0.670 |
Why?
|
HIV Integrase Inhibitors | 1 | 2022 | 164 | 0.660 |
Why?
|
Viruses | 1 | 2023 | 371 | 0.660 |
Why?
|
Yellow Fever | 1 | 2020 | 54 | 0.650 |
Why?
|
Metagenome | 2 | 2020 | 464 | 0.630 |
Why?
|
Microsatellite Repeats | 1 | 2021 | 784 | 0.620 |
Why?
|
Epidemics | 2 | 2022 | 514 | 0.610 |
Why?
|
Computer Systems | 1 | 2020 | 466 | 0.600 |
Why?
|
Meat | 1 | 2021 | 588 | 0.600 |
Why?
|
Africa, Western | 10 | 2023 | 160 | 0.590 |
Why?
|
Africa | 9 | 2024 | 725 | 0.580 |
Why?
|
Genes, MDR | 2 | 2008 | 36 | 0.580 |
Why?
|
Child, Preschool | 55 | 2021 | 42500 | 0.570 |
Why?
|
Zoonoses | 5 | 2023 | 181 | 0.550 |
Why?
|
Sex Ratio | 7 | 2011 | 107 | 0.530 |
Why?
|
Infant | 44 | 2021 | 36386 | 0.500 |
Why?
|
Rhabdoviridae | 1 | 2015 | 5 | 0.490 |
Why?
|
Rhabdoviridae Infections | 1 | 2015 | 9 | 0.490 |
Why?
|
Disaster Planning | 1 | 2021 | 559 | 0.490 |
Why?
|
Hematocrit | 10 | 2019 | 621 | 0.480 |
Why?
|
Staphylococcal Infections | 1 | 2024 | 1393 | 0.480 |
Why?
|
Rabbits | 1 | 2021 | 4734 | 0.480 |
Why?
|
Polymerase Chain Reaction | 10 | 2021 | 6069 | 0.460 |
Why?
|
Child | 56 | 2023 | 80564 | 0.450 |
Why?
|
Humans | 140 | 2024 | 765968 | 0.450 |
Why?
|
Haplotypes | 7 | 2021 | 2728 | 0.440 |
Why?
|
Hepatitis B | 3 | 2023 | 707 | 0.430 |
Why?
|
Metagenomics | 3 | 2023 | 473 | 0.430 |
Why?
|
Genetic Variation | 10 | 2021 | 6610 | 0.410 |
Why?
|
Drug Therapy, Combination | 22 | 2021 | 6309 | 0.380 |
Why?
|
Pandemics | 9 | 2024 | 8703 | 0.380 |
Why?
|
DNA, Protozoan | 5 | 2012 | 226 | 0.350 |
Why?
|
Polymorphism, Single Nucleotide | 5 | 2022 | 16047 | 0.350 |
Why?
|
Mycobacterium tuberculosis | 1 | 2021 | 1917 | 0.350 |
Why?
|
Animals | 46 | 2024 | 168764 | 0.340 |
Why?
|
Mutation, Missense | 2 | 2011 | 2589 | 0.330 |
Why?
|
Selection, Genetic | 4 | 2014 | 878 | 0.330 |
Why?
|
Linkage Disequilibrium | 3 | 2021 | 1997 | 0.330 |
Why?
|
Hepatitis B, Chronic | 2 | 2023 | 412 | 0.320 |
Why?
|
Mefloquine | 5 | 2012 | 55 | 0.320 |
Why?
|
Coronavirus Infections | 3 | 2023 | 3100 | 0.310 |
Why?
|
Plasmodium berghei | 3 | 2015 | 161 | 0.300 |
Why?
|
Antigens, Protozoan | 4 | 2021 | 314 | 0.300 |
Why?
|
Merozoite Surface Protein 1 | 3 | 2021 | 36 | 0.290 |
Why?
|
Genome, Bacterial | 2 | 2024 | 797 | 0.280 |
Why?
|
Antibodies, Neutralizing | 3 | 2024 | 2010 | 0.280 |
Why?
|
Proguanil | 1 | 2006 | 11 | 0.270 |
Why?
|
Male | 66 | 2023 | 363698 | 0.270 |
Why?
|
Seroepidemiologic Studies | 3 | 2024 | 404 | 0.270 |
Why?
|
Female | 64 | 2024 | 396112 | 0.270 |
Why?
|
Cytochromes b | 1 | 2006 | 35 | 0.270 |
Why?
|
Naphthoquinones | 1 | 2006 | 61 | 0.270 |
Why?
|
Sierra Leone | 8 | 2020 | 171 | 0.260 |
Why?
|
Parasitic Sensitivity Tests | 3 | 2012 | 90 | 0.260 |
Why?
|
Epitopes, T-Lymphocyte | 2 | 2020 | 825 | 0.260 |
Why?
|
Communicable Diseases | 1 | 2014 | 874 | 0.260 |
Why?
|
Sequence Analysis, DNA | 8 | 2021 | 4772 | 0.260 |
Why?
|
N-Acetylglucosaminyltransferases | 2 | 2021 | 168 | 0.260 |
Why?
|
Microbial Sensitivity Tests | 2 | 2024 | 1971 | 0.260 |
Why?
|
Rifampin | 2 | 2021 | 351 | 0.260 |
Why?
|
Enzyme-Linked Immunospot Assay | 2 | 2024 | 126 | 0.250 |
Why?
|
Genotype | 8 | 2023 | 13024 | 0.250 |
Why?
|
Hepatitis B virus | 3 | 2023 | 530 | 0.240 |
Why?
|
Murinae | 2 | 2022 | 18 | 0.240 |
Why?
|
Hemorrhagic Fevers, Viral | 2 | 2016 | 23 | 0.240 |
Why?
|
Point Mutation | 2 | 2006 | 1590 | 0.230 |
Why?
|
HIV-1 | 1 | 2022 | 6944 | 0.230 |
Why?
|
Molecular Diagnostic Techniques | 3 | 2020 | 618 | 0.220 |
Why?
|
Communicable Diseases, Emerging | 2 | 2018 | 150 | 0.220 |
Why?
|
Multilocus Sequence Typing | 1 | 2024 | 102 | 0.220 |
Why?
|
Endemic Diseases | 3 | 2017 | 189 | 0.220 |
Why?
|
Cross Reactions | 3 | 2020 | 824 | 0.220 |
Why?
|
Animals, Domestic | 1 | 2023 | 55 | 0.210 |
Why?
|
Area Under Curve | 6 | 2017 | 1638 | 0.210 |
Why?
|
Swine | 2 | 2024 | 5988 | 0.210 |
Why?
|
Evolution, Molecular | 4 | 2024 | 1889 | 0.210 |
Why?
|
Goats | 1 | 2023 | 166 | 0.210 |
Why?
|
Immunoglobulin G | 4 | 2024 | 4528 | 0.210 |
Why?
|
Saliva | 3 | 2013 | 851 | 0.200 |
Why?
|
Disease Reservoirs | 3 | 2018 | 124 | 0.200 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2004 | 238 | 0.200 |
Why?
|
Amino Acid Substitution | 1 | 2006 | 1740 | 0.190 |
Why?
|
Capreomycin | 1 | 2021 | 14 | 0.190 |
Why?
|
Adolescent | 23 | 2021 | 88835 | 0.190 |
Why?
|
High-Throughput Nucleotide Sequencing | 4 | 2021 | 3655 | 0.190 |
Why?
|
Democratic Republic of the Congo | 2 | 2019 | 87 | 0.190 |
Why?
|
Capacity Building | 1 | 2024 | 266 | 0.190 |
Why?
|
Environmental Microbiology | 1 | 2021 | 47 | 0.190 |
Why?
|
Ciprofloxacin | 2 | 2015 | 314 | 0.180 |
Why?
|
Mammals | 2 | 2024 | 1125 | 0.180 |
Why?
|
Sequence Analysis, RNA | 3 | 2020 | 2034 | 0.180 |
Why?
|
Phylogeography | 2 | 2018 | 71 | 0.180 |
Why?
|
Liberia | 2 | 2023 | 176 | 0.180 |
Why?
|
Vesiculovirus | 1 | 2020 | 52 | 0.170 |
Why?
|
Computational Biology | 2 | 2024 | 3559 | 0.170 |
Why?
|
Laboratories, Hospital | 1 | 2021 | 193 | 0.160 |
Why?
|
Chlorpheniramine | 3 | 2008 | 13 | 0.160 |
Why?
|
Nucleic Acids | 1 | 2022 | 193 | 0.160 |
Why?
|
Sulfalene | 3 | 2008 | 3 | 0.160 |
Why?
|
Fluoroquinolones | 1 | 2021 | 307 | 0.160 |
Why?
|
Treatment Outcome | 24 | 2021 | 65188 | 0.160 |
Why?
|
Blood | 3 | 2010 | 597 | 0.160 |
Why?
|
Carrier Proteins | 1 | 2012 | 4913 | 0.160 |
Why?
|
Viral Envelope Proteins | 2 | 2020 | 640 | 0.160 |
Why?
|
Dogs | 1 | 2024 | 3822 | 0.160 |
Why?
|
Ritonavir | 1 | 2021 | 330 | 0.160 |
Why?
|
Africa South of the Sahara | 5 | 2022 | 751 | 0.160 |
Why?
|
Histamine H1 Antagonists | 3 | 2008 | 100 | 0.160 |
Why?
|
Haplorhini | 1 | 2019 | 520 | 0.150 |
Why?
|
HIV Infections | 2 | 2022 | 17533 | 0.150 |
Why?
|
Cattle | 1 | 2024 | 3801 | 0.150 |
Why?
|
Chromosome Mapping | 1 | 2006 | 4618 | 0.150 |
Why?
|
Administration, Oral | 5 | 2021 | 4015 | 0.150 |
Why?
|
Receptors, Virus | 1 | 2021 | 651 | 0.140 |
Why?
|
Plants, Medicinal | 2 | 2010 | 166 | 0.140 |
Why?
|
Escherichia coli Infections | 1 | 2021 | 519 | 0.140 |
Why?
|
Survivors | 3 | 2022 | 2372 | 0.140 |
Why?
|
Rodentia | 1 | 2018 | 261 | 0.140 |
Why?
|
Immunity, Cellular | 1 | 2022 | 1555 | 0.140 |
Why?
|
Likelihood Functions | 1 | 2020 | 993 | 0.130 |
Why?
|
Drug Resistance, Viral | 1 | 2022 | 866 | 0.130 |
Why?
|
DNA, Bacterial | 1 | 2021 | 1477 | 0.130 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2020 | 4642 | 0.130 |
Why?
|
Biological Evolution | 3 | 2016 | 1072 | 0.130 |
Why?
|
Sesquiterpenes | 2 | 2007 | 175 | 0.130 |
Why?
|
Alleles | 3 | 2012 | 6897 | 0.120 |
Why?
|
Adult | 21 | 2023 | 223044 | 0.120 |
Why?
|
South Africa | 1 | 2021 | 1867 | 0.120 |
Why?
|
Vaccines | 1 | 2024 | 841 | 0.120 |
Why?
|
Filoviridae | 1 | 2014 | 15 | 0.120 |
Why?
|
Asymptomatic Diseases | 1 | 2018 | 586 | 0.120 |
Why?
|
Prevalence | 7 | 2022 | 15842 | 0.120 |
Why?
|
Markov Chains | 1 | 2018 | 968 | 0.120 |
Why?
|
Drug Administration Schedule | 3 | 2021 | 4850 | 0.120 |
Why?
|
Young Adult | 12 | 2023 | 59889 | 0.120 |
Why?
|
Viral Vaccines | 1 | 2020 | 597 | 0.110 |
Why?
|
Diagnostic Tests, Routine | 1 | 2020 | 790 | 0.110 |
Why?
|
Plant Extracts | 2 | 2010 | 496 | 0.110 |
Why?
|
Promethazine | 3 | 2009 | 29 | 0.110 |
Why?
|
Inhibitory Concentration 50 | 2 | 2012 | 461 | 0.110 |
Why?
|
Clinical Laboratory Techniques | 1 | 2019 | 747 | 0.110 |
Why?
|
Health Resources | 1 | 2020 | 949 | 0.110 |
Why?
|
Databases, Nucleic Acid | 1 | 2014 | 204 | 0.110 |
Why?
|
Thiazoles | 1 | 2021 | 1529 | 0.110 |
Why?
|
Mutation | 7 | 2023 | 30198 | 0.100 |
Why?
|
Population Surveillance | 2 | 2021 | 2590 | 0.100 |
Why?
|
Antitubercular Agents | 1 | 2021 | 1384 | 0.100 |
Why?
|
DNA, Viral | 3 | 2023 | 2199 | 0.100 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2019 | 3807 | 0.100 |
Why?
|
Aminoquinolines | 1 | 2012 | 102 | 0.100 |
Why?
|
Child Health Services | 1 | 2017 | 645 | 0.090 |
Why?
|
Renal Dialysis | 1 | 2020 | 1799 | 0.090 |
Why?
|
Genetic Testing | 1 | 2024 | 3595 | 0.090 |
Why?
|
Body Weight | 3 | 2012 | 4622 | 0.090 |
Why?
|
Influenza, Human | 1 | 2022 | 1539 | 0.090 |
Why?
|
Public Health | 1 | 2024 | 2680 | 0.090 |
Why?
|
Bayes Theorem | 1 | 2018 | 2354 | 0.090 |
Why?
|
Genome, Human | 2 | 2014 | 4448 | 0.090 |
Why?
|
Antiviral Agents | 2 | 2021 | 3050 | 0.090 |
Why?
|
Genetic Vectors | 1 | 2020 | 3404 | 0.090 |
Why?
|
Middle Aged | 11 | 2023 | 223009 | 0.080 |
Why?
|
Desiccation | 1 | 2009 | 77 | 0.080 |
Why?
|
Polymorphism, Restriction Fragment Length | 2 | 2010 | 766 | 0.080 |
Why?
|
Pregnancy Complications, Infectious | 2 | 2019 | 2187 | 0.080 |
Why?
|
Medicine, Traditional | 1 | 2010 | 88 | 0.080 |
Why?
|
Specimen Handling | 2 | 2015 | 704 | 0.080 |
Why?
|
Membrane Proteins | 1 | 2006 | 7851 | 0.080 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2010 | 412 | 0.080 |
Why?
|
Proteins | 1 | 2004 | 5995 | 0.080 |
Why?
|
Acute Disease | 4 | 2018 | 7232 | 0.080 |
Why?
|
Time Factors | 7 | 2021 | 40065 | 0.080 |
Why?
|
Disease | 1 | 2014 | 676 | 0.080 |
Why?
|
Multigene Family | 1 | 2012 | 1080 | 0.080 |
Why?
|
Arm | 1 | 2011 | 589 | 0.080 |
Why?
|
Acute Kidney Injury | 1 | 2020 | 1946 | 0.070 |
Why?
|
Herpes Labialis | 1 | 2008 | 28 | 0.070 |
Why?
|
Gene Dosage | 2 | 2011 | 1216 | 0.070 |
Why?
|
Blood Chemical Analysis | 1 | 2009 | 433 | 0.070 |
Why?
|
Chromatography, High Pressure Liquid | 4 | 2013 | 1526 | 0.070 |
Why?
|
Brazil | 1 | 2012 | 1248 | 0.070 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2015 | 10729 | 0.070 |
Why?
|
Cross-Sectional Studies | 3 | 2024 | 26318 | 0.070 |
Why?
|
Terminology as Topic | 1 | 2014 | 1534 | 0.070 |
Why?
|
Base Sequence | 2 | 2015 | 12403 | 0.070 |
Why?
|
Interleukins | 1 | 2012 | 791 | 0.070 |
Why?
|
Plasmodium | 1 | 2010 | 248 | 0.070 |
Why?
|
Follow-Up Studies | 7 | 2017 | 39193 | 0.070 |
Why?
|
Orosomucoid | 1 | 2006 | 47 | 0.070 |
Why?
|
Atovaquone | 1 | 2006 | 56 | 0.070 |
Why?
|
Multicenter Studies as Topic | 2 | 2023 | 1731 | 0.070 |
Why?
|
Hepatomegaly | 1 | 2006 | 83 | 0.070 |
Why?
|
Travel | 2 | 2017 | 806 | 0.070 |
Why?
|
Amino Acid Sequence | 3 | 2020 | 13400 | 0.070 |
Why?
|
Treatment Failure | 3 | 2012 | 2652 | 0.060 |
Why?
|
Rats | 1 | 2022 | 23707 | 0.060 |
Why?
|
Quinolines | 3 | 2018 | 769 | 0.060 |
Why?
|
Senegal | 1 | 2006 | 257 | 0.060 |
Why?
|
Guinea | 2 | 2016 | 33 | 0.060 |
Why?
|
Drug Monitoring | 1 | 2012 | 962 | 0.060 |
Why?
|
Age Distribution | 1 | 2011 | 2858 | 0.060 |
Why?
|
Chromatography, Liquid | 1 | 2009 | 990 | 0.060 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3223 | 0.060 |
Why?
|
Medicine, African Traditional | 1 | 2005 | 31 | 0.060 |
Why?
|
Fever | 3 | 2024 | 1603 | 0.060 |
Why?
|
Databases as Topic | 1 | 2007 | 471 | 0.060 |
Why?
|
Malawi | 1 | 2006 | 315 | 0.060 |
Why?
|
Anti-Bacterial Agents | 1 | 2024 | 7478 | 0.060 |
Why?
|
Risk Factors | 6 | 2017 | 74840 | 0.060 |
Why?
|
Codon | 1 | 2006 | 595 | 0.060 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2010 | 1333 | 0.060 |
Why?
|
Case-Control Studies | 2 | 2015 | 22223 | 0.060 |
Why?
|
Sensitivity and Specificity | 5 | 2020 | 14652 | 0.060 |
Why?
|
Seizures | 1 | 2017 | 3000 | 0.060 |
Why?
|
Genes, pol | 1 | 2023 | 53 | 0.060 |
Why?
|
Recurrence | 2 | 2008 | 8501 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 2 | 2017 | 6499 | 0.050 |
Why?
|
DNA Copy Number Variations | 1 | 2012 | 2045 | 0.050 |
Why?
|
Program Evaluation | 1 | 2011 | 2499 | 0.050 |
Why?
|
Microscopy | 2 | 2008 | 901 | 0.050 |
Why?
|
False Negative Reactions | 1 | 2004 | 573 | 0.050 |
Why?
|
Immunoassay | 2 | 2018 | 741 | 0.050 |
Why?
|
Hepatitis B e Antigens | 1 | 2023 | 135 | 0.050 |
Why?
|
Age Factors | 5 | 2014 | 18380 | 0.050 |
Why?
|
Hepatitis B Antibodies | 1 | 2023 | 156 | 0.050 |
Why?
|
Herpesvirus 1, Human | 1 | 2008 | 743 | 0.050 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2006 | 2745 | 0.050 |
Why?
|
Sequence Alignment | 1 | 2006 | 2171 | 0.050 |
Why?
|
Prospective Studies | 7 | 2023 | 54802 | 0.050 |
Why?
|
Hepatitis B Surface Antigens | 1 | 2023 | 294 | 0.050 |
Why?
|
Genetic Loci | 1 | 2011 | 2631 | 0.050 |
Why?
|
Emergency Service, Hospital | 1 | 2021 | 7875 | 0.050 |
Why?
|
Biodiversity | 1 | 2024 | 346 | 0.050 |
Why?
|
Ribavirin | 2 | 2014 | 395 | 0.050 |
Why?
|
Drug Interactions | 3 | 2014 | 1417 | 0.050 |
Why?
|
Genetic Markers | 1 | 2007 | 2601 | 0.050 |
Why?
|
Nitro Compounds | 1 | 2021 | 74 | 0.050 |
Why?
|
Half-Life | 2 | 2013 | 644 | 0.040 |
Why?
|
Molecular Epidemiology | 2 | 2017 | 471 | 0.040 |
Why?
|
Biomedical Research | 1 | 2016 | 3458 | 0.040 |
Why?
|
T-Lymphocytes | 1 | 2018 | 10261 | 0.040 |
Why?
|
Genome-Wide Association Study | 2 | 2024 | 12807 | 0.040 |
Why?
|
Survival Analysis | 4 | 2014 | 10070 | 0.040 |
Why?
|
Hospitals, Teaching | 2 | 2017 | 1158 | 0.040 |
Why?
|
Immune Sera | 1 | 2020 | 601 | 0.040 |
Why?
|
HLA-DQ Antigens | 1 | 2020 | 190 | 0.040 |
Why?
|
Reproducibility of Results | 4 | 2021 | 20124 | 0.040 |
Why?
|
Recombinant Proteins | 2 | 2020 | 6493 | 0.040 |
Why?
|
Attitude to Health | 1 | 2008 | 2020 | 0.040 |
Why?
|
Hematuria | 1 | 2020 | 230 | 0.040 |
Why?
|
Antibodies, Monoclonal | 1 | 2016 | 9249 | 0.040 |
Why?
|
Verapamil | 2 | 2012 | 242 | 0.040 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2017 | 4562 | 0.040 |
Why?
|
Viral Load | 2 | 2021 | 3386 | 0.040 |
Why?
|
Congo | 1 | 2018 | 13 | 0.040 |
Why?
|
Oligonucleotide Probes | 1 | 2019 | 417 | 0.040 |
Why?
|
Drug Repositioning | 1 | 2021 | 246 | 0.040 |
Why?
|
Molecular Sequence Data | 2 | 2012 | 17594 | 0.040 |
Why?
|
Culicidae | 1 | 2019 | 110 | 0.040 |
Why?
|
Severity of Illness Index | 3 | 2021 | 15880 | 0.040 |
Why?
|
Fluorescence | 1 | 2020 | 753 | 0.040 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2021 | 639 | 0.040 |
Why?
|
Linear Models | 2 | 2018 | 5876 | 0.040 |
Why?
|
Validation Studies as Topic | 1 | 2018 | 162 | 0.040 |
Why?
|
Biological Assay | 1 | 2020 | 627 | 0.040 |
Why?
|
Proteinuria | 1 | 2020 | 607 | 0.040 |
Why?
|
DNA Barcoding, Taxonomic | 1 | 2018 | 135 | 0.040 |
Why?
|
Macaca fascicularis | 1 | 2020 | 907 | 0.040 |
Why?
|
Serologic Tests | 1 | 2019 | 382 | 0.040 |
Why?
|
Microfluidics | 1 | 2022 | 651 | 0.030 |
Why?
|
Arenavirus | 1 | 2016 | 8 | 0.030 |
Why?
|
Population Dynamics | 1 | 2018 | 314 | 0.030 |
Why?
|
Standard of Care | 1 | 2021 | 567 | 0.030 |
Why?
|
Climate | 1 | 2017 | 147 | 0.030 |
Why?
|
Genes, Reporter | 1 | 2020 | 1524 | 0.030 |
Why?
|
Immunization | 1 | 2020 | 1219 | 0.030 |
Why?
|
Immunity, Humoral | 1 | 2020 | 605 | 0.030 |
Why?
|
Virology | 1 | 2016 | 77 | 0.030 |
Why?
|
Gene Library | 1 | 2019 | 1067 | 0.030 |
Why?
|
Oligonucleotides | 1 | 2019 | 561 | 0.030 |
Why?
|
Species Specificity | 1 | 2020 | 2406 | 0.030 |
Why?
|
Demography | 1 | 2020 | 1641 | 0.030 |
Why?
|
Epitope Mapping | 1 | 2016 | 300 | 0.030 |
Why?
|
Geography | 1 | 2017 | 652 | 0.030 |
Why?
|
Green Fluorescent Proteins | 1 | 2020 | 2060 | 0.030 |
Why?
|
Gene Expression Regulation | 1 | 2012 | 11888 | 0.030 |
Why?
|
Antibody Specificity | 1 | 2016 | 1061 | 0.030 |
Why?
|
Communicable Disease Control | 1 | 2020 | 856 | 0.030 |
Why?
|
Exanthema | 1 | 2018 | 502 | 0.030 |
Why?
|
Pregnancy | 3 | 2023 | 30260 | 0.030 |
Why?
|
Immunologic Memory | 1 | 2020 | 1375 | 0.030 |
Why?
|
Primate Diseases | 1 | 2012 | 15 | 0.030 |
Why?
|
Logistic Models | 2 | 2018 | 13266 | 0.030 |
Why?
|
Immunoglobulin M | 1 | 2018 | 1528 | 0.030 |
Why?
|
England | 1 | 2014 | 533 | 0.030 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2016 | 1679 | 0.030 |
Why?
|
Virus Diseases | 1 | 2019 | 718 | 0.030 |
Why?
|
Antigens, Bacterial | 1 | 2018 | 1146 | 0.030 |
Why?
|
Bacterial Toxins | 1 | 2018 | 924 | 0.030 |
Why?
|
Metabolic Clearance Rate | 1 | 2013 | 360 | 0.020 |
Why?
|
Antibodies | 1 | 2020 | 2417 | 0.020 |
Why?
|
Sequence Deletion | 1 | 2016 | 1495 | 0.020 |
Why?
|
Host-Pathogen Interactions | 1 | 2020 | 1461 | 0.020 |
Why?
|
Internationality | 1 | 2017 | 1007 | 0.020 |
Why?
|
Genetics, Medical | 1 | 2014 | 334 | 0.020 |
Why?
|
Point-of-Care Systems | 1 | 2020 | 1217 | 0.020 |
Why?
|
Vomiting | 1 | 2014 | 647 | 0.020 |
Why?
|
Health | 1 | 2014 | 397 | 0.020 |
Why?
|
Phenanthrenes | 1 | 2011 | 65 | 0.020 |
Why?
|
Incidence | 2 | 2023 | 21480 | 0.020 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2014 | 791 | 0.020 |
Why?
|
Hypoxanthine | 1 | 2010 | 28 | 0.020 |
Why?
|
Gestational Age | 1 | 2019 | 3609 | 0.020 |
Why?
|
Primates | 1 | 2012 | 518 | 0.020 |
Why?
|
Diamines | 1 | 2010 | 60 | 0.020 |
Why?
|
ROC Curve | 1 | 2017 | 3620 | 0.020 |
Why?
|
Spectrophotometry, Ultraviolet | 1 | 2009 | 199 | 0.020 |
Why?
|
International Cooperation | 1 | 2016 | 1432 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2021 | 10383 | 0.020 |
Why?
|
Epitopes | 1 | 2016 | 2523 | 0.020 |
Why?
|
Tritium | 1 | 2010 | 702 | 0.020 |
Why?
|
Histamine Antagonists | 1 | 2009 | 93 | 0.020 |
Why?
|
Erythrocytes, Abnormal | 2 | 1960 | 122 | 0.020 |
Why?
|
Sickle Cell Trait | 2 | 1960 | 86 | 0.020 |
Why?
|
Organic Chemicals | 1 | 2010 | 211 | 0.020 |
Why?
|
Benzothiazoles | 1 | 2010 | 246 | 0.020 |
Why?
|
Retrospective Studies | 4 | 2021 | 81514 | 0.020 |
Why?
|
Community Medicine | 1 | 2008 | 23 | 0.020 |
Why?
|
Disease Management | 1 | 2019 | 2535 | 0.020 |
Why?
|
Pregnancy Outcome | 1 | 2019 | 2966 | 0.020 |
Why?
|
Reference Standards | 1 | 2012 | 1013 | 0.020 |
Why?
|
Viral Proteins | 1 | 2015 | 1797 | 0.020 |
Why?
|
Abdominal Pain | 1 | 2014 | 1069 | 0.020 |
Why?
|
Patient Compliance | 2 | 2008 | 2692 | 0.020 |
Why?
|
Seasons | 1 | 2014 | 1524 | 0.020 |
Why?
|
Cohort Studies | 2 | 2023 | 41649 | 0.020 |
Why?
|
Diarrhea | 1 | 2014 | 1316 | 0.020 |
Why?
|
Glycoproteins | 1 | 2015 | 2195 | 0.020 |
Why?
|
Common Cold | 1 | 2008 | 63 | 0.020 |
Why?
|
Community Health Services | 1 | 2012 | 657 | 0.020 |
Why?
|
Rural Population | 2 | 2008 | 2317 | 0.020 |
Why?
|
Life Cycle Stages | 1 | 2008 | 161 | 0.020 |
Why?
|
Pilot Projects | 1 | 2021 | 8733 | 0.020 |
Why?
|
Suppositories | 1 | 2007 | 16 | 0.020 |
Why?
|
Desipramine | 1 | 2006 | 183 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2018 | 8529 | 0.020 |
Why?
|
Models, Molecular | 1 | 2016 | 5379 | 0.020 |
Why?
|
Government Programs | 1 | 2008 | 278 | 0.020 |
Why?
|
Artemia | 1 | 2005 | 6 | 0.020 |
Why?
|
Lethal Dose 50 | 1 | 2005 | 70 | 0.020 |
Why?
|
Staining and Labeling | 1 | 2010 | 1072 | 0.020 |
Why?
|
Sex Factors | 1 | 2019 | 10603 | 0.020 |
Why?
|
Odds Ratio | 1 | 2017 | 9649 | 0.020 |
Why?
|
Injections, Intramuscular | 1 | 2007 | 552 | 0.020 |
Why?
|
Sentinel Surveillance | 1 | 2007 | 293 | 0.020 |
Why?
|
Methanol | 1 | 2005 | 90 | 0.020 |
Why?
|
Toxicity Tests | 1 | 2005 | 111 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2021 | 15398 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2018 | 12056 | 0.010 |
Why?
|
Calcium Channel Blockers | 1 | 2006 | 686 | 0.010 |
Why?
|
Mortality | 1 | 2014 | 2904 | 0.010 |
Why?
|
Drug Synergism | 1 | 2007 | 1749 | 0.010 |
Why?
|
Health Services Accessibility | 1 | 2020 | 5508 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2011 | 6203 | 0.010 |
Why?
|
Clinical Trials as Topic | 2 | 2009 | 8041 | 0.010 |
Why?
|
Mice | 3 | 2015 | 81819 | 0.010 |
Why?
|
Disease Progression | 1 | 2019 | 13632 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2020 | 5370 | 0.010 |
Why?
|
Focus Groups | 1 | 2008 | 1459 | 0.010 |
Why?
|
Genetic Association Studies | 1 | 2011 | 2741 | 0.010 |
Why?
|
Filariasis | 1 | 1961 | 26 | 0.010 |
Why?
|
Health Education | 1 | 2008 | 1060 | 0.010 |
Why?
|
Anemia, Sickle Cell | 2 | 1960 | 1067 | 0.010 |
Why?
|
Interviews as Topic | 1 | 2008 | 2739 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2020 | 26346 | 0.010 |
Why?
|
Cameroon | 4 | 1961 | 79 | 0.010 |
Why?
|
Cell Survival | 1 | 2010 | 5747 | 0.010 |
Why?
|
Leishmaniasis | 1 | 1960 | 66 | 0.010 |
Why?
|
Ulcer | 1 | 1960 | 201 | 0.010 |
Why?
|
Gene Expression | 1 | 2011 | 7584 | 0.010 |
Why?
|
Guideline Adherence | 1 | 2008 | 2243 | 0.010 |
Why?
|
Regression Analysis | 1 | 2007 | 6322 | 0.010 |
Why?
|
Blood Group Antigens | 1 | 1959 | 183 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2008 | 5302 | 0.010 |
Why?
|
Qualitative Research | 1 | 2008 | 3139 | 0.010 |
Why?
|
Aged | 2 | 2021 | 171117 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2006 | 3715 | 0.010 |
Why?
|
Caregivers | 1 | 2008 | 2307 | 0.010 |
Why?
|
Internet | 1 | 2007 | 3106 | 0.010 |
Why?
|
Survival Rate | 1 | 2008 | 12795 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2011 | 18293 | 0.010 |
Why?
|
Research | 1 | 1959 | 1975 | 0.010 |
Why?
|
United States | 1 | 2014 | 72903 | 0.000 |
Why?
|